A Phase 4 interventional study of Methocarbamol and Standard Opioid in Ventral Hernia and Inguinal Hernia, sponsored by Prisma Health-Upstate. Active, not recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-10.
Sponsored by Prisma Health-Upstate · Phase 4, Interventional, and Treatment
Among 94 studies in Hernia, Ventral with a site in United States — 14 open to participants now, 24 under way, none of them phase 3. Hernia, Ventral · United States.
Among the 94 studies in Hernia, Ventral with a site in United States, this one is the 20th largest by enrollment of the 70 interventional ones that give a count, is one of 8 that started in 2022, is one of 8 in phase 4, reaches primary completion later than 15 of the 23 other live ones, and was the 65th registered.
230 studies on the registry are indexed under Hernia, Ventral; 45 are open to participants now.
Browse Hernia, Ventral studies →14 of the 94 studies in Hernia, Ventral with a site in United States are open now. Recruiting first, the newest first:
Northwestern University · Sites in United States
Ages 18+
Northwestern University · Sites in United States
Ages 18–80
AbbVie · Sites in United States
Ages 18–80
The Cleveland Clinic · Sites in United States
Ages 18+
Lucas Beffa · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 26 Hernia, Ventral studies recruiting now, 19 (73%) set no upper age limit and 4 (15%) stop at 75 or younger; 1 takes children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
94 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 8 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 164 is above the median of 90 across 153 interventional studies indexed under Hernia, Ventral.
Median enrollment 100 across the 70 interventional studies, 63 across the 24 observational. Of the 59 that completed or were terminated, 31 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
32 of 94 have an industry lead sponsor. The 10 most frequent:
Prisma Health-Upstate is the lead sponsor of 76 studies on the registry; 7 are open to participants now.
Of its 12 completed or terminated interventional studies of FDA-regulated products, 10 (83%) have results posted.
Prisma Health-Upstate has 4 studies filed under Hernia, Ventral — fewer than ten, so there is no comparison to draw.
10 of the studies in Hernia, Ventral with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04718168W.L.Gore & AssociatesGORE® ENFORM Biomaterial Product Study | 2026-12 |
| NCT07639281Tori DotsonOpioid Education Ventral Hernia Repair | 2026-12 |
| NCT07874724University of South FloridaCryoneurolysis for Abdominal Wall Relaxation Prior to Ventral Hernia Repair | 2027-03-01 |
| NCT04779918Tela Bio IncVentral or Inguinal Hernia, Robotically Repaired With OviTex Mesh | 2027-03-30 |
| NCT06874413Prisma Health-UpstateTargeted Prehabilitation With Physical Exercise and Inspiratory Muscle Training for Elderly Frail Patients Prior to Ventral Hernia Repair | 2027-04-30 |
Add all 10 to your calendar (.ics) → With an account.
Among the 94 studies in Hernia, Ventral with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to gather information on methocarbamol as a pain management treatment for ventral or inguinal hernia repair.
Methocarbamol has been part of the pain management treatment for both inpatient and outpatient procedures at Prisma Health. This study will compare the outcomes of patients who receive methocarbamol, those who receive the standard opioid pain management treatment, and those who receive methocarbamol plus the standard opioid pain management treatment.
Participants will be randomized into one of the study groups listed below.
Primary ventral hernia repair or inguinal hernia repair:
Group 1: standard opioid after surgery Group 2: methocarbamol after surgery
Open or robotic ventral hernia repair outpatient:
Group 1: standard opioid after surgery Group 2: standard opioid plus methocarbamol after surgery
Open or robotic ventral hernia repair inpatient:
Group 1: standard opioid at discharge Group 2: standard opioid plus methocarbamol at discharge
A total of 200 participants will be included in the study.
Participation will last for about 30 days after surgery.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Primary ventral hernias, including umbilical, epigastric, and Spigelian hernias. Primary or recurrent inguinal hernias.
Drug: Methocarbamol · Drug: Standard Opioid
Open repair of ventral incisional hernias. Robotic repair of ventral primary or incisional hernias.
Drug: Standard Opioid · Drug: Standard opioid plus methocarbamol
Open repair of ventral incisional hernias. Robotic repair of ventral primary or incisional hernias.
Drug: Standard Opioid · Drug: Standard opioid plus methocarbamol
Methocarbamol after surgery
Standard opioid after surgery or at discharge
Standard opioid plus methocarbamol after surgery or at discharge
Proportion of patients requiring a rescue opioid prescription
The proportion of patients requiring a rescue opioid prescription will be compared between the study and control groups using the Fisher's Exact Test (bivariate analysis). Multiple logistic regression analysis will then be used to test for a difference in this outcome, adjusting for any baseline differences between the 2 study groups.
Time frame: 30 days post surgery
Average total morphine milligram equivalents (MME) consumption
Average total MME consumption will be compared between the study and control groups using either the Student's T-test or the Wilcoxon Rank Sum Test (depends on distribution of the data -- parametric vs. non-parametric).
Time frame: 30 days post surgery
European Registry of Abdominal Wall Hernias (EuraHS) Quality of Life tool scores
Scale of 0-10, where 0 = no pain and 10 = worst pain imaginable. Outcome will be compared between the study and control groups using either the Student's T-test or the Wilcoxon Rank Sum Test. Statistical tests used are dependent on the data distribution -- parametric vs. non-parametric).
Time frame: 30 days post surgery
Visual Analog Scale pain scores
Scale of 0-10, where 0 = no pain and 10 = worst pain imaginable. Outcome will be compared between the study and control groups using either the Student's T-test or the Wilcoxon Rank Sum Test. Statistical tests used are dependent on the data distribution -- parametric vs. non-parametric).
Time frame: 7 days post surgery
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2022 (actual). Primary completion is estimated for Jun 2027, 60 months after the start.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Methocarbamol
Prisma Health-Upstate